NPM1-mutated acute myeloid leukemia: from bench to bedside
The nucleophosmin (NPM1) gene encodes for a multifunctional protein with prominent
nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations …
nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations …
How I diagnose and treat NPM1-mutated AML
Mutations of the nucleophosmin (NPM1) gene, encoding for a nucleolar multifunctional
protein, occur in approximately one-third of adult acute myeloid leukemia (AML). NPM1 …
protein, occur in approximately one-third of adult acute myeloid leukemia (AML). NPM1 …
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
CA Lachowiez, N Long, J Saultz, A Gandhi… - Blood …, 2023 - ashpublications.org
Risk stratification in acute myeloid leukemia (AML) remains principle in survival
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
C Rausch, M Rothenberg-Thurley, A Dufour… - Leukemia, 2023 - nature.com
Abstract The revised 2022 European LeukemiaNet (ELN) AML risk stratification system
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …
Venetoclax plus 3+ 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial
H Wang, L Mao, M Yang, P Qian, H Lu… - The Lancet …, 2022 - thelancet.com
Background Adults with acute myeloid leukaemia have unsatisfactory clinical outcomes and
rates of complete remission. Venetoclax combined with azacytidine or low-dose cytarabine …
rates of complete remission. Venetoclax combined with azacytidine or low-dose cytarabine …
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
Abstract Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of
acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with …
acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with …
Poor survival and differential impact of genetic features of black patients with acute myeloid leukemia
Clinical outcome of patients with acute myeloid leukemia (AML) is associated with
cytogenetic and molecular factors and patient demographics (eg, age and race). We …
cytogenetic and molecular factors and patient demographics (eg, age and race). We …
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
Clinical outcome of patients with acute myeloid leukemia (AML) is associated with
demographic and genetic features. Although the associations of acquired genetic alterations …
demographic and genetic features. Although the associations of acquired genetic alterations …
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
Abstract The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and
management of acute myeloid leukemia (AML) have become fundamental guidelines to …
management of acute myeloid leukemia (AML) have become fundamental guidelines to …
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients …
Abstract The European LeukemiaNet (ELN) recently proposed a revised recommendation
for the diagnosis and management of acute myeloid leukemia (AML) in adults, recognized …
for the diagnosis and management of acute myeloid leukemia (AML) in adults, recognized …